Previous 10 | Next 10 |
Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain PR Newswire - ZYNRELEF is the first and only extended-release local anesthetic approved by Health Canada - SAN DIEGO , March 17, 2022 ...
The following slide deck was published by Heron Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Heron Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
So far, 2022 has been an ugly year for a lot of stocks. But if you look out over the next five years, you can find some amazing opportunities. Our roundtable of three Motley Fool contributors has found three biotech stocks that might be 11-baggers in five years. Patrick Bafuma is bullis...
Heron Therapeutics had a productive 2021 with several corporate and commercial achievements that will set the company up for future growth. Subsequently, Heron obtained approval for a substantially expanded indication only five months after launch. Furthermore, the company filed a...
Heron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference PR Newswire SAN DIEGO , March 2, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) a commercial-stage biotechnology company focused on improving the lives of patients by developin...
Shares of the small-cap biotech Heron Therapeutics (NASDAQ: HRTX) are down by a noteworthy 19.2% as of 2:48 p.m. ET Tuesday afternoon. The drugmaker's shares are cratering today in response to its disappointing 2021 fourth-quarter results. What's the specific culprit behind ...
Gainers: Avenue Therapeutics (NASDAQ:ATXI) +165%. CTI BioPharma (NASDAQ:CTIC) +60%. UserTesting (NYSE:USER) +31%. Oak Street Health (NYSE:OSH) +25%. iQIYI (NASDAQ:IQ) +24%. Veritiv (NYSE:VRTV) +18%. TaskUs (NASDAQ:TASK) +17%. Danimer Scientific (NYSE:DNMR) +17%. LivePerson (NASDAQ:LPSN) +16%....
Heron Therapeutics (HRTX -21.3%) stock fell following in Q4 results. Q4 net product sales rose +0.24% Y/Y to $20.66M, which failed to beat analysts' estimates. Net product sales for ZYNRELEF were $0.8M in Q4. The pain drug became commercially available in the U.S. on July 1. The ap...
Gainers: CTI BioPharma (NASDAQ:CTIC) +40%. Oak Street Health (NYSE:OSH) +23%. AVITA Medical (NASDAQ:RCEL) +15%. Axsome Therapeutics (NASDAQ:AXSM) +14%. Protagonist Therapeutics (NASDAQ:PTGX) +12%. Losers: GoodRx Holdings (NASDAQ:GDRX) -40%. Semler Scientific...
Heron Therapeutics, Inc. (HRTX) Q4 2021 Results Conference Call February 28, 2022 04:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - Chairman and CEO John Poyhonen - President and Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...